USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
Evotec today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of the German biotech firm's DNA damage response (DDR) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. 8 July 2019
A new biopharma research company, Frontier Medicines, has launched in California USA, via a Series A Preferred Stock financing round of $67 million. 26 June 2019
Asian healthcare platform Novena Global Lifecare Group is to join with two other groups to create the Sino-Singapore Healthcare Fund with a target size of $150 million. 25 June 2019
Europe's biggest privately-held biotech BioNTech has been in the news recently, with reports the company could be about to raise just shy of a billion dollars in a US listing. 25 June 2019
US protein engineering company Codexis says that Casdin Capital, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested around $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement. 20 June 2019
Japanese conglomerate Fujifilm Corp has signed an agreement to invest 300 million yen ($2.8 million) into a biotech venture, PuREC Co, through underwriting its third-party allocation of shares. 20 June 2019
Belgian immunotherapies developer Imcyse today announces that it has raised 35 million euros ($39.5 million) in a Series B financing round and through other channels. Imcyse is a spin-off from Belgium’s Katholieke Universiteit Leuven (KUL). 18 June 2019
Oncologie, a company that is using proprietary biomarkers to drive development of new drugs for cancer, has closed an $80 Series B financing. 12 June 2019
Swiss oncology-focused drug discovery firm ADC Therapeutics today announced that it has closed a $76 million expansion of its Series E financing, bringing the total gross proceeds raised in the Series E financing to $276 million. 12 June 2019
Texas-based regenerative medicine and cell therapy company InGeneron has raised a further $23 million to advance a pivotal program in rotator cuff tendinopathy, a degenerative and often chronic condition found in a person’s shoulder. 12 June 2019
In the latest sign that the consumption of cannabis for medicinal purposes is being legitimized, the Church of England has reversed its previous policy of refusing to invest in schemes seeking to profit from the drug’s use. 11 June 2019
Evotec has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (TB). 11 June 2019
Shares in UK-based antibiotics developer Motif Bio are now worth just a tenth of their value of four months ago after more bad news about iclaprim, the company’s lead product. 7 June 2019
Boston, USA-based Third Rock Ventures today announced today the closing of Third Rock Ventures V, raising $770 million in an oversubscribed fund, and marking the largest in its 12-year history. 6 June 2019
Investors stand to play a crucial role in driving healthcare sustainability as well as supporting scientific innovation, write Nathalie Flury and Michael Schröter, founding partners at Swiss asset manager Viopas Partners, and Kate Dion, healthcare value communications consultant at 3D Communications, in an Expert View piece. 24 May 2019
ElevateBio, a newly-launched cell and gene therapy incubator, has announced that AlloVir, formerly known as ViraCyte, has joined its fledgling portfolio. 23 May 2019
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news